May 7, 2020

Massachusetts researchers advance a novel gene-based COVID-19 vaccine

By: Judy Mathias

Editor's Note

Researchers at the Massachusetts Eye and Ear, Massachusetts General Hospital, and Mass General Brigham, announced May 5 their progress towards the testing and development of an experimental vaccine against SARS-CoV-2 called AAVCOVID.

The vaccine is currently in preclinical development with a plan to begin clinical testing in humans later this year.

Sponsored Message

Intramuscular vaccination with AAVCOVID will deliver the genetic code for antigens from the SARS-CoV-2 Spike protein, which will cause an immune response and prevent infection.

AAV [adeno-associated viral] vector is a clinically established gene transfer technology that is also rapidly adaptable, so that if a new strain of the SARS-CoV-2 virus emerges, the genetic code inside the vaccine can be exchanged for an updated genetic code and processed into an updated vaccine in weeks, the researcher say.


Sign Up For OR a.m.
Sign up for the free OR a.m. eLetter to get news like this in your inbox every morning!

OR Manager Jobs
Live chat by BoldChat